Mirum Pharmaceuticals Inc (MIRM) Q4 2025 Earnings Call Transcript

Why It Matters

The results demonstrate Mirum's ability to scale rare‑disease revenues while funding a late‑stage pipeline that could unlock multi‑billion‑dollar market opportunities.

Key Takeaways

• 2025 sales hit $521M, 55% YoY growth.
• 2026 sales forecast $630‑650M, driven by Livmarli.
• Cash rose to $391M; private placements added $268.5M.
• R&D spend to jump $150M in 2026 for brolobitug.
• Four pivotal readouts slated within 18 months.

Pulse Analysis

Mirum Pharmaceuticals closed 2025 with $521 million in net product sales, a 55 percent year‑over‑year increase that outpaced its own guidance. The growth was anchored by Livmarli’s expanding footprint in the United States and abroad, as well as robust demand for its bile‑acid portfolio. 5 million from two private placements tied to the Bluejay acquisition. Management now projects 2026 revenue of $630‑$650 million, underscoring confidence in commercial momentum.

The pipeline is the next engine of value. Mirum added a Phase III brolobitug program for chronic hepatitis delta virus, a rare disease with limited therapy, and expects interim data from the AZURE‑1 study in the second quarter of 2026. Simultaneously, the VISTA trial of volixibat in primary sclerosing cholangitis is on track for top‑line results later this year, positioning the company to launch the first approved PSC treatment. Additional late‑stage studies—EXPAND, VANTAGE, and the Fast‑Track BLOOM trial in Fragile X—are also advancing on schedule.

From an investment perspective, Mirum’s blend of growing commercial revenues and a funded, late‑stage pipeline creates a compelling risk‑adjusted profile. The anticipated readouts could unlock multi‑billion‑dollar market opportunities across rare cholestatic and viral liver disorders, while the company’s strong balance sheet limits dilution risk. Competitors lack approved therapies in PSC, giving volixibat a pricing advantage, and brolobitug may capture a sizable share of the hepatitis delta market if efficacy is confirmed. Analysts will watch cash‑flow trends through 2027 as R&D spend peaks and then recedes.